media
News and Publications
Read the latest news, announcements, and research from IMIDomics.
In the News
Mar 26, 2025
2025
Dra. Sara Marsal recognized among the 10 most valued in Rheumatology by Diario ABC
https://www.abc.esIn the News
Mar 3, 2025
2025
We are proud to be recognized in UCB’s 2024 Integrated Annual Report, highlighting the impact of our partnership in shaping the future of IMID treatment
https://www.ucb.comIn the News
Feb 13, 2025
2025
DocTIS, in the final stretch to revolutionize the treatment of immune-mediated inflammatory diseases
https://doctis.eu/Press Releases
Sep 18, 2024
2024
IMIDomics, Inc. Appoints Life Sciences Industry Leader Matthias Evers, Ph.D., to Board of Directors
https://www.businesswire.com/news/In the News
Mar 11, 2024
2024
Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes
Seven-chain adaptive immune receptor repertoireIn the News
Mar 4, 2024
2024
UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases
https://www.ucb.com/stories-mediaPress Releases
Dec 6, 2023
2023
IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development
https://www.businesswire.com/news/In the News
Nov 15, 2023
2023
IMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory Team
https://www.businesswire.com/news/Press Releases
Oct 11, 2023
2023
IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs
https://www.businesswire.com/newsPress Releases
Oct 4, 2023
2023
IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases
https://www.businesswire.com/newsPublications
Sep 28, 2023
2023
Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes
https://academic.oup.com/In the News
Sep 27, 2023
2023
Founder of IMIDomics receives the Trifermed Award for Social Impact in Healthcare
https://awards.trifermed.com/In the News
Sep 27, 2023
2023
Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases
https://www.businesswire.com/newsSep 6, 2023
2023
IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases
www.businesswire.com/newsPublications
Aug 29, 2023
2023
Toward Precision Medicine in Atopic Dermatitis Using Molecular-Based Approaches
https://pubmed.ncbi.nlm.nih.govPublications
Apr 1, 2023
2023
Influenza Adverse Events in Patients with rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis in the Tofacitinib Clinical Development Programs
pubmed.ncbi.nlm.nih.govIn the News
Dec 7, 2022
2022
IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board
Businesswire.comPublications
Dec 1, 2022
2022
Association of class II HLA alleles with susceptibility to develop immune-mediated diseases in Paraguayan patients
onlinelibrary.wiley.comPublications
Nov 1, 2022
2022
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
pubmed.ncbi.nlm.nih.govPublications
Aug 1, 2022
2022
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
pubmed.ncbi.nlm.nih.govIn the News
Mar 23, 2022
2022
CataloniaBio & HealthTech has awarded IMIDomics with the Bioèxit Award | Award acceptance speech by co-founder and CMO, Dr. Sara Marsal
Cataloniabioht.orgIn the News
Feb 15, 2022
2022
IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE
Businesswire.comPublications
Jan 1, 2022
2022
Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19
pubmed.ncbi.nlm.nih.govPublications
Jan 1, 2022
2022
Food groups associated with IMIDS: Mendelian randomization and disease severity study
doi.orgIn the News
Dec 7, 2021
2021
IMIDomics™ Announces Scientific and Business Advisory Boards
Businesswire.comPublications
Dec 1, 2021
2021
Mapping the human genetic architecture of COVID-19
pubmed.ncbi.nlm.nih.govPublications
Dec 1, 2021
2021
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
pubmed.ncbi.nlm.nih.govIn the News
Oct 7, 2021
2021
IMIDomics sponsors the online Symposium “Combination therapies in common diseases: clinical and translational challenges”, October 7th 2021
Doctis.euIn the News
Jul 27, 2021
2021
IMIDomics™ Closes $16.5 Million Series A Financing to Advance its Precision Discovery Platform for Immune-Mediated Inflammatory Diseases
Businesswire.comIn the News
Jul 20, 2021
2021
IMIDomics co-organizes symposium "Combination therapies in common diseases: clinical and translational challenges"
Doctis.euPublications
Jun 1, 2021
2021
Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19
pubmed.ncbi.nlm.nih.govPublications
May 1, 2021
2021
Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis
thelancet.comPublications
Apr 1, 2021
2021
Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
doi.orgPublications
Apr 1, 2021
2021
Food groups associated with IMIDS: Mendelian randomization and disease severity study
doi.orgPublications
Apr 1, 2021
2021
Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
doi.orgIn the News
Oct 16, 2020
2020
Drug candidate for severe COVID-19 identified by IMIDomics and VHIR Rheumatology Group selected for NIH clinical trial
Nih.govPublications
Jun 1, 2020
2020
Genomewide Association Study of Severe Covid-19 with Respiratory Failure
pubmed.ncbi.nlm.nih.govPublications
Jun 1, 2020
2020
Complement genes contribute sex-biased vulnerability in diverse disorders
pubmed.ncbi.nlm.nih.govIn the News
May 20, 2020
2020
IMIDomics funds a study that identifies a new drug candidate to prevent severe COVID-19
Arxiv.orgPublications
May 1, 2020
2020
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
pubmed.ncbi.nlm.nih.govIn the News
Feb 2, 2020
2020
IMIDomics and Gossamer Bio Enter into a Strategic Collaboration to Advance the Development of Novel Treatments for Patients with Immune-Mediated Inflammatory Diseases
Businesswire.comPublications
Feb 1, 2020
2020
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
doi.orgPublications
Jan 1, 2020
2020
Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis
doi.orgPublications
Jan 1, 2020
2020
A questionnaire-based study on contraceptive practice in patients with rheumatic disease found no significant difference in age-matched healthy controls
doi.orgIn the News
Dec 1, 2019
2019
IMIDomics granted Horizon 2020 project on Systems approaches for the discovery of combinatorial therapies for complex disorders
Doctis.euPublications
Mar 1, 2019
2019
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
https://pubmed.ncbi.nlm.nih.govPublications
Jan 1, 2019
2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease.
europepmc.orgPublications
Jan 1, 2019
2019
A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in rheumatoid arthritis
europepmc.orgPublications
Jan 1, 2019
2019
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease
doi.orgPublications
Jan 1, 2018
2018
Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus
doi.orgPublications
Jan 1, 2018
2018
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
doi.orgIn the News
Mar 26, 2025
Dra. Sara Marsal recognized among the 10 most valued in Rheumatology by Diario ABC
https://www.abc.esIn the News
Mar 3, 2025
We are proud to be recognized in UCB’s 2024 Integrated Annual Report, highlighting the impact of our partnership in shaping the future of IMID treatment
https://www.ucb.comIn the News
Feb 13, 2025
DocTIS, in the final stretch to revolutionize the treatment of immune-mediated inflammatory diseases
https://doctis.eu/In the News
Mar 11, 2024
Seven-chain adaptive immune receptor repertoire analysis in rheumatoid arthritis reveals novel features associated with disease and clinically relevant phenotypes
Seven-chain adaptive immune receptor repertoireIn the News
Mar 4, 2024
UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases
https://www.ucb.com/stories-mediaIn the News
Nov 15, 2023
IMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory Team
https://www.businesswire.com/news/In the News
Sep 27, 2023
Founder of IMIDomics receives the Trifermed Award for Social Impact in Healthcare
https://awards.trifermed.com/In the News
Sep 27, 2023
Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases
https://www.businesswire.com/newsIn the News
Dec 7, 2022
IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board
Businesswire.comIn the News
Mar 23, 2022
CataloniaBio & HealthTech has awarded IMIDomics with the Bioèxit Award | Award acceptance speech by co-founder and CMO, Dr. Sara Marsal
Cataloniabioht.orgIn the News
Feb 15, 2022
IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE
Businesswire.comIn the News
Oct 7, 2021
IMIDomics sponsors the online Symposium “Combination therapies in common diseases: clinical and translational challenges”, October 7th 2021
Doctis.euIn the News
Jul 27, 2021
IMIDomics™ Closes $16.5 Million Series A Financing to Advance its Precision Discovery Platform for Immune-Mediated Inflammatory Diseases
Businesswire.comIn the News
Jul 20, 2021
IMIDomics co-organizes symposium "Combination therapies in common diseases: clinical and translational challenges"
Doctis.euIn the News
Oct 16, 2020
Drug candidate for severe COVID-19 identified by IMIDomics and VHIR Rheumatology Group selected for NIH clinical trial
Nih.govIn the News
May 20, 2020
IMIDomics funds a study that identifies a new drug candidate to prevent severe COVID-19
Arxiv.orgIn the News
Feb 2, 2020
IMIDomics and Gossamer Bio Enter into a Strategic Collaboration to Advance the Development of Novel Treatments for Patients with Immune-Mediated Inflammatory Diseases
Businesswire.comIn the News
Dec 1, 2019
IMIDomics granted Horizon 2020 project on Systems approaches for the discovery of combinatorial therapies for complex disorders
Doctis.euPublications
2023
Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes
https://academic.oup.com/Publications
2023
Toward Precision Medicine in Atopic Dermatitis Using Molecular-Based Approaches
https://pubmed.ncbi.nlm.nih.govPublications
2023
Influenza Adverse Events in Patients with rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis in the Tofacitinib Clinical Development Programs
pubmed.ncbi.nlm.nih.govPublications
2022
Association of class II HLA alleles with susceptibility to develop immune-mediated diseases in Paraguayan patients
onlinelibrary.wiley.comPublications
2022
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
pubmed.ncbi.nlm.nih.govPublications
2022
Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study
pubmed.ncbi.nlm.nih.govPublications
2022
Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19
pubmed.ncbi.nlm.nih.govPublications
2022
Food groups associated with IMIDS: Mendelian randomization and disease severity study
doi.orgPublications
2021
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
pubmed.ncbi.nlm.nih.govPublications
2021
Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19
pubmed.ncbi.nlm.nih.govPublications
2021
Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis
thelancet.comPublications
2021
Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
doi.orgPublications
2021
Food groups associated with IMIDS: Mendelian randomization and disease severity study
doi.orgPublications
2021
Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
doi.orgPublications
2020
Genomewide Association Study of Severe Covid-19 with Respiratory Failure
pubmed.ncbi.nlm.nih.govPublications
2020
Complement genes contribute sex-biased vulnerability in diverse disorders
pubmed.ncbi.nlm.nih.govPublications
2020
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
pubmed.ncbi.nlm.nih.govPublications
2020
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
doi.orgPublications
2020
Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis
doi.orgPublications
2020
A questionnaire-based study on contraceptive practice in patients with rheumatic disease found no significant difference in age-matched healthy controls
doi.orgPublications
2019
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
https://pubmed.ncbi.nlm.nih.govPublications
2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease.
europepmc.orgPublications
2019
A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in rheumatoid arthritis
europepmc.orgPublications
2019
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease
doi.orgPublications
2018
Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus
doi.orgPublications
2018
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
doi.orgPress Releases
Sep 18, 2024
IMIDomics, Inc. Appoints Life Sciences Industry Leader Matthias Evers, Ph.D., to Board of Directors
https://www.businesswire.com/news/Press Releases
Dec 6, 2023
IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory Disease Treatment Research and Development
https://www.businesswire.com/news/Press Releases
Oct 11, 2023
IMIDomics Establishes a License and Collaboration Partnership with the University of Barcelona to Advance Treatments for IMIDs
https://www.businesswire.com/newsPress Releases
Oct 4, 2023
IMIDomics Announces Strategic Agreement with WuXi Biologics to Advance IMB1001 Antibody Development for Immune-Mediated Inflammatory Diseases
https://www.businesswire.com/newsDiscovering and developing the next generation of medicines for immune-mediated inflammatory diseases